Development of Free Fatty Acid Receptor 4 (FFA4/GPR120) Agonists in Health Science
Biomolecules & Therapeutics
; : 22-30, 2021.
Article
en En
| WPRIM
| ID: wpr-874304
Biblioteca responsable:
WPRO
ABSTRACT
Till the 21st century, fatty acids were considered as merely building blocks for triglycerides, phospholipids, or cholesteryl esters.However, the discovery of G protein-coupled receptors (GPCRs) for free fatty acids at the beginning of the 21st century challenged that idea and paved way for a new field of research, merged into the field of receptor pharmacology for intercellular lipid mediators.Among the GPCRs for free fatty acids, free fatty acid receptor 4 (FFA4, also known as GPR120) recognizes long-chain polyunsaturated fatty acids such as DHA and EPA. It is significant in drug discovery because it regulates obesity-induced metaflammation and GLP-1 secretion. Our study reviews information on newly developed FFA4 agonists and their application in pathophysiologic studies and drug discovery. It also offers a potency comparison of the FFA4 agonists in an AP-TGF-α shedding assay.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Biomolecules & Therapeutics
Año:
2021
Tipo del documento:
Article